Voiding dysfunction in patients with human T-lymphotropic virus type-1-associated myelopathy (HAM).
about
3D domain swapping: a mechanism for oligomer assemblyAtomic solvation parameters applied to molecular dynamics of proteins in solutionProperties and crystal structure of a beta-barrel folding mutantX-ray crystal structures of the oxidized and reduced forms of the rubredoxin from the marine hyperthermophilic archaebacterium pyrococcus furiosusThe cause of urinary symptoms among Human T Lymphotropic Virus Type I (HLTV-I) infected patients: a cross sectional study.Where metal ions bind in proteinsDetrusor Arreflexia as an End Stage of Neurogenic Bladder in HAM/TSP?Contribution of a single heavy chain residue to specificity of an anti-digoxin monoclonal antibody.A preference-based free-energy parameterization of enzyme-inhibitor binding. Applications to HIV-1-protease inhibitor designDirect measurement of salt-bridge solvation energies using a peptide model system: implications for protein stability.Folding simulations of alanine-based peptides with lysine residues.Monte Carlo docking with ubiquitin.Calculation of the free energy of association for protein complexesAtomic solvation parameters in the analysis of protein-protein docking results.Electrostatics of a simple membrane model using Green's functions formalism.Inclusion of solvation free energy with molecular mechanics energy: alanyl dipeptide as a test case.Hydrophobic regions on protein surfaces. Derivation of the solvation energy from their area distribution in crystallographic protein structures.Lower urinary tract symptoms of neurological origin in urological practice.
P2860
Q24675333-0702212E-D8AF-4201-9C1C-D11FA69781DAQ24676145-E1A8193C-862A-42AF-8083-A71AC6C92B95Q27621556-4E55FFF0-1734-4CE7-980D-34D1F9D7891BQ27642037-01D2542B-CC49-471A-B933-915A75A818B8Q33277961-D4342A71-1B5E-461E-B297-8DB602F47A49Q33708616-EEA79AB9-0B36-41C2-AEF2-D3892CB76CDCQ34897044-4EA835B9-85E5-461A-964B-CCE6BFA56971Q36278518-073E492B-4686-46C8-B84C-E4E2924F3FE7Q36279404-226ABD3A-18EF-450B-B7EC-CFC89BF40949Q37682818-498F19BC-250C-4798-B105-DD8F918F40D5Q39653480-3D5DB9C1-2D88-44C8-B6D5-19DFE8C154CAQ41828214-13645331-9EDE-462F-B95B-40F4E7C7D5F1Q42034773-D6C4CA9E-E306-49B5-AED6-6E4F6E98A427Q42076740-46F31A40-2A3E-44B9-ABA5-6D2F04BCC3DDQ42272383-C1A9F3C0-9FB3-40A1-85B8-EA4D8F584625Q42842155-BDA214C9-6902-4953-B86A-6A3ACA464524Q42845402-09BE6038-5F2C-4D33-AB00-DA4AB0CEADFBQ48320393-66916035-6DC2-4D49-9BEB-2DC95350F314
P2860
Voiding dysfunction in patients with human T-lymphotropic virus type-1-associated myelopathy (HAM).
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
Voiding dysfunction in patient ...... 1-associated myelopathy (HAM).
@en
Voiding dysfunction in patient ...... s type-1-associated myelopathy
@nl
type
label
Voiding dysfunction in patient ...... 1-associated myelopathy (HAM).
@en
Voiding dysfunction in patient ...... s type-1-associated myelopathy
@nl
prefLabel
Voiding dysfunction in patient ...... 1-associated myelopathy (HAM).
@en
Voiding dysfunction in patient ...... s type-1-associated myelopathy
@nl
P2093
P2860
P356
P1433
P1476
Voiding dysfunction in patient ...... 1-associated myelopathy (HAM).
@en
P2093
P2860
P304
P356
10.1038/SC.1989.32
P577
1989-06-01T00:00:00Z